ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Acute megakaryoblastic leukemia with CBFA2T3::GLIS2 fusion gene: 3 cases report and literature review].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study retrospectively analyzed the clinical manifestations, genetic characteristics, treatment courses, and prognoses of patients with pediatric acute megakaryoblastic leukemia (AMKL) with CBFA2T3::GLIS2 fusion treated at the Institute of Hematology, Chinese Academy of Medical Sciences. Further, the diagnostic and therapeutic features of this rare AMKL subtype, in conjunction with domestic and international literature, were summarized. The patients comprised one male and two females, with a median age at onset of 16 months (range, 8-19 months). Central nervous system leukemia was present at diagnosis in two cases. All were classified as acute myeloid leukemia (AML) -M(7) according to the French-American-British classification, with immunophenotypes demonstrating CD56 positivity and human leukocyte antigen-DR negativity. All patients showed complex abnormal karyotypes, including trisomy 21 in two cases. All patients achieved morphological complete remission (CR) after chemotherapy. However, all patients experienced early relapse, with a median relapse time of 11 months (range, 7-13 months), and the median overall survival time was 16 months (range, 15-47 months). One patient relapsed after the first hematopoietic stem cell transplantation and relapsed again after a second transplantation and is currently receiving palliative care. The other two patients discontinued treatment after relapse and subsequently died. These results reveal that CBFA2T3::GLIS2 fusion-positive AMKL is a highly aggressive subtype, frequently associated with a CD56-positive, HLA-DR-negative immunophenotype, and complex karyotypes, with trisomy 21 observed in a subset of cases. This subtype is characterized by a high relapse rate and an extremely poor prognosis. At present, effective therapeutic approaches are lacking, with an urgent need to explore novel treatment strategies to improve clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.